Written by Jayasri P · Last updated 26 August 2026 · Statutory references current to the Income-tax Act 2025 and the Income-tax Rules 2026.
In an Indian pharmaceutical group, each entity is paid for what it does. A contract research unit earns a cost-based margin, a contract or loan-licence manufacturer earns a routine manufacturing return, and a distributor earns a distribution margin. The residual profit follows the entity that owns and controls the product intangible under Section 165 of the Income-tax Act 2025.
Transfer pricing for pharmaceutical companies is unusually contested because the same molecule passes through three or four related parties before it reaches a patient, with research sitting in one entity, active ingredient and formulation manufacturing in another, and promotion to prescribers in a third. Each step generates a claim on profit, and Indian transfer pricing decides how much of that claim each entity may keep.
Transfer pricing advisory services in India: what does a pharmaceutical group need?
A pharmaceutical group needs three things from a transfer pricing adviser: a defensible characterisation of every Indian entity, a benchmarking file supporting the margin each one reports, and a documented position on who owns the product intangible. Method selection matters far less than characterisation, because comparable data cannot rescue a file that has assigned the wrong role to the entity it is testing.
Steadfast Business Consulting (SBC), recognised as a Notable Transfer Pricing Firm 2024 by ITR World Tax and founded by Big 4 alumni, lists contract manufacturing arrangements, royalty structures and research and development cost allocation among the pharmaceutical matters covered by its transfer pricing services in India, alongside documentation, benchmarking and safe harbour work.
How does the pharmaceutical value chain split into transfer pricing entities?
The chain splits into four recognisable roles, each carrying its own return, and those roles matter far more than entity names because a single Indian company frequently performs two of them and must report a separate margin for each.
| Value chain role | What the entity does | Usual characterisation | Where its return comes from | Principal exposure |
|---|---|---|---|---|
| Contract research | Runs studies and development batches on the principal’s instructions | Routine service provider, insignificant risk | Mark-up on operating expense | Whether it in fact carries development risk |
| Contract or loan-licence manufacturing | Produces active ingredients or formulations to a specified process | Routine manufacturer | Mark-up on cost, or a resale-based return | Whether it owns the process or the registration |
| Marketing and distribution | Sells finished goods in India and carries the field force | Limited-risk or full-fledged distributor | Distribution margin on sales | Promotional spending treated as a separate transaction |
| Principal or intangible owner | Holds the registration, funds development, bears market risk | Entrepreneur | Residual profit after routine returns | Whether it controls the functions it is paid for |
Why does a single Indian company often occupy more than one role?
Because Indian pharmaceutical operations grew organically rather than by design. A company that began as an export manufacturer typically added a development centre and then a domestic sales division, without ever separating those transactions in its transfer pricing file. Rule 84(1)(f) of the Income-tax Rules 2026 requires a record of financial estimates prepared for the business as a whole and for each division or product separately, so the obligation to look through the entity to its activities already sits in the documentation rule.
Segmental accounts are the answer, built from the cost accounting system rather than reconstructed at year end. A single profit and loss account covering research, manufacturing and distribution invites the Transfer Pricing Officer to pick the segment with the highest margin.
Who owns the product intangible in a pharmaceutical group?
The entity that funds, directs and controls the development of a product owns the return on it, not necessarily the entity named on the certificate. Pharmaceutical files fail here more than anywhere else. Ownership in this sector is spread across several instruments at once, and a file naming only one of them has not answered the question it was written to answer.
Is the dossier separate from the patent?
Yes, and treating them as one thing is a common drafting error. A pharmaceutical product carries a patent or process know-how, a regulatory dossier, the marketing authorisation granted on that dossier, and a brand, and because those four can sit in four different entities each generates a return that has to be identified separately.
For a generic group the dossier is often the most valuable, embodying years of bioequivalence and stability work.
What happens when the Indian entity funds development but the parent holds the registration?
The funding entity is entitled to more than a service fee, and how much more depends on whether it also controlled the work. Legal title alone does not carry the residual profit, and the analysis establishing economic entitlement is set out in our note on who owns the return on group intangibles.
Where a licence settles the arrangement instead, the rate becomes the pressure point, and a rate copied from a database without a comparability adjustment rarely survives. Building one is addressed in what royalty rate is defensible under Indian transfer pricing.
How are contract research and development arrangements priced?
Contract research is priced on a mark-up over operating expense, applied through the transactional net margin method in most Indian files. The arm’s length price is determined under Section 165 of the Income-tax Act 2025, with the prescribed methods set out in Rule 79 of the Income-tax Rules 2026 and the selection criteria in Rule 80.
The cost base is where the argument starts. Pass-through costs such as clinical trial site payments and third-party laboratory charges are routinely excluded from the base carrying the mark-up, and that exclusion must be justified rather than simply applied.
What is the safe harbour margin for contract research on generic pharmaceutical drugs?
An operating profit margin of not less than 24% on operating expense, where the aggregate operating revenue from the transaction does not exceed ₹300 crore in the tax year. This sits in the table at Rule 89(2) of the Income-tax Rules 2026, made under the power in Section 167 of the Income-tax Act 2025.
Three conditions carry it: Rule 87(1)(d) treats a person providing contract research and development services wholly or partly relating to generic pharmaceutical drugs, with insignificant risk, to a foreign principal as an eligible assessee, Rule 88(d) makes that provision an eligible international transaction, and Rule 90 governs the exercise of the option.
Note what the threshold excludes. An arrangement generating more than ₹300 crore falls outside the safe harbour entirely and returns to full benchmarking, a real cliff for a group approaching that level. The wider framework is set out in our overview of safe harbour rules under Indian transfer pricing regulations.
What disqualifies a research unit from insignificant-risk treatment?
Conduct, not contract. Rule 87(3) directs that the foreign principal must perform the economically significant functions in the research cycle, including conceptualisation, product design and strategic direction, and must supply the funds and the intangibles the work requires.
The rule then closes the obvious escape route, providing that where a contract obliges the foreign principal to control risk but the conduct shows the Indian entity doing so, the contractual terms are not the final determinant. The Indian entity must also hold no ownership right, legal or economic, over the outcome of the research.
How is contract or loan-licence manufacturing remunerated?
A contract manufacturer earns a routine return, because it converts inputs to a specified process without owning the process, the registration or the market. The mark-up is normally tested on total cost. Comparables come from independent formulation or active ingredient manufacturers rather than from integrated pharmaceutical companies, whose margins reflect intangibles a contract manufacturer does not hold.
Does a loan-licence arrangement change the characterisation?
It changes the facts to be documented, not the principle. Where one company manufactures using the licence and premises of another, the party holding the product registration and bearing market risk takes the residual, while the party contributing capacity earns only a routine return for the capacity it supplies.
Which of the two the Indian entity actually is, is the question. An Indian company manufacturing on its own licence but to a related party’s specification, formula and quality release sits closer to a contract manufacturer than the licence position alone suggests.
Which method applies to a manufacturing arrangement?
Cost plus or the transactional net margin method in most Indian manufacturing files, with the resale price method reserved for cases where the Indian entity resells without substantial transformation. The choice is governed by Rule 80, and the two cost-based routes are compared in which transfer pricing method applies to your transaction.
Once the method generates multiple prices, Rule 81 states that a margin which is outside the range generated will not be reset to the closest edge of that range.
Why does marketing spend in pharmaceutical distribution attract adjustment?
Because pharmaceutical promotion is large, prescriber-directed and long-lived, which makes it look like brand building rather than selling. An Indian distributor typically funds a field force of medical representatives, prescriber engagement, medical education and launch programmes, at a share of sales well above ordinary consumer distribution.
The department’s position is that spending beyond what an independent distributor would incur enhances a brand the foreign affiliate owns, and so requires compensation. The taxpayer’s position is narrower. That spending buys current-period sales, inside the Indian entity’s own margin.
What is the threshold question before any adjustment?
Whether an international transaction exists at all. An adjustment presupposes a transaction between associated enterprises within Section 163 of the Income-tax Act 2025, with associated enterprise defined in Section 162, and that transaction must be established on evidence rather than inferred from a comparison of spending levels.
There the file does its work. A group able to show that the Indian entity set its own promotional plan, kept the commercial benefit in its own margin, and was neither directed nor selectively reimbursed by the brand owner has answered the question before it is asked, and the documents proving that point cannot be created after a notice arrives.
What documentation does a pharmaceutical group have to keep?
The information and documents listed in Rule 84 of the Income-tax Rules 2026, prescribed under Section 171 of the Income-tax Act 2025. The obligation applies where the aggregate value of international transactions recorded in the books exceeds ₹1 crore in the tax year, under Rule 84(2).
Rule 84(1)(e) carries most of the weight, requiring a description of the functions performed, risks assumed and assets employed by the Indian entity and by each associated enterprise, which is where a chain spanning research, manufacturing and marketing is either explained or exposed.
The accountant’s report under Section 172 is furnished separately, in Form 48, which replaced Form 3CEB, and an accountant prepares that report while the Transfer Pricing Officer examines the file it accompanies on a reference made under Section 166.
Where should a pharmaceutical group start?
With characterisation, before benchmarking. Map each Indian entity to one of the four roles above, confirm its accounts can produce a segmental margin for every role it performs, and only then select comparables. If your group has added a development centre, changed its manufacturing model or launched a domestic portfolio since the last documentation cycle, put the arrangement in front of the SBC transfer pricing team before the current year closes.
Frequently Asked Questions
Does the safe harbour cover contract manufacturing in pharmaceuticals?
No. The safe harbour provisions under Rule 89(2) of the Income-tax Rules 2026 provide for contract research and development services relating to generic pharmaceutical drugs, not for manufacture of pharmaceutical products. Manufacturing contracts are compared in the general manner under Rule 80, with no specific margin to be applied to determine the arm’s length price.
What margin does a contract research unit have to report?
Not less than 24% of operating expense to use the safe harbour, and only where the transaction’s aggregate operating revenue stays within ₹300 crore for the tax year. Outside the safe harbour there is no fixed margin, and the reported result must fall inside the arm’s length range determined under Rule 81.
Who owns the regulatory dossier for transfer pricing purposes?
The entity that funded and controlled the development work, which is not always the entity holding the marketing authorisation. Legal title is a starting point rather than the answer. Where an Indian entity built the dossier, its entitlement has to be quantified and documented instead of being absorbed into a service fee.
Is promotional spending automatically a transfer pricing adjustment?
No. An adjustment requires an international transaction between associated enterprises to be established first, on evidence. A comparison showing that the Indian entity spends more on promotion than selected comparables does not by itself create that transaction, although such comparisons continue to appear in show-cause notices.
Do these rules apply to a purely domestic pharmaceutical group?
Only where the transactions are specified domestic transactions within Section 164 of the Income-tax Act 2025, and then only where their aggregate value exceeds ₹20 crore in the tax year. Groups below that threshold fall outside the regime, though international transactions remain covered.